Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

BACKGROUND: Colorectal cancers (CRCs) expressing programmed death ligand 1 (PD-L1) have poor prognosis. In the multicohort KEYNOTE-028 trial, the anti–PD-1 antibody pembrolizumab was evaluated in 20 PD-L1–positive advanced solid tumors. Herein, we report results for the advanced CRC cohort. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neil, Bert H., Wallmark, John M., Lorente, David, Elez, Elena, Raimbourg, Judith, Gomez-Roca, Carlos, Ejadi, Samuel, Piha-Paul, Sarina A., Stein, Mark N., Abdul Razak, Albiruni R., Dotti, Katia, Santoro, Armando, Cohen, Roger B., Gould, Marlena, Saraf, Sanatan, Stein, Karen, Han, Sae-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746232/
https://www.ncbi.nlm.nih.gov/pubmed/29284010
http://dx.doi.org/10.1371/journal.pone.0189848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746232/
https://www.ncbi.nlm.nih.gov/pubmed/29284010
http://dx.doi.org/10.1371/journal.pone.0189848

Ejemplares similares